过去几年来,华尔街一直对孟山都的前景有点不以为然,部分原因是因为市场反对转基因作物的呼声甚高。但近几个财季,分析师却开始逐步调高孟山都的股价。这家公司公布第一财季的业绩后,富国银行(Wells Fargo)就这么做了。今年四月,这家公司宣布又成功收获一个财季后,摩根大通(J.P. Morgan)也随之跟进。上周三,花旗集团(Citigroup)的P.J.祖维卡干脆称孟山都为“我们在农业领域最钟情的名字”,同时把它的目标股价设为125美元——而当天交易价格很快就超越这个价位(上周四,孟山都的股价略有回调,但仍然高于每股125美元)。
Such sentiments are also found on the buy side. In May, Larry Robbins of the hedge fund Glenview Capital Management insisted during the Sohn Investment Conference that Monsanto’s shares — then trading at about $110 — were way undervalued. Though he complained about Monsanto “hoarding capital” with its $15.8 billion in “dry powder” (cash), he enthused about the company’s prospects. It enjoys “massive barriers to entry” and “perpetual local monopolies” thanks to farmers basically signing on with Monsanto for life. He noted that while “corn demand will double” over the next 15 or 20 years, “acres won’t,” necessitating far greater yields. “In the real world, we cannot solve world hunger on an organic basis,” Robbins said.
【全球转基因种子生意为什么能稳赚不赔】相关文章:
最新
2020-09-15
2020-09-15
2020-09-15
2020-09-15
2020-09-15
2020-09-15